Next Article in Journal
Wherein the Authors Attempt to Minimize the Confusion Generated by Their Study “Breast Cancer Mortality after a Diagnosis of Ductal Carcinoma In Situ” by Several Commentators Who Disagree with Them and a Few Who Don’t: A Qualitative Study
Previous Article in Journal
Acute Care Hospitalization Near the End of Life for Cancer Patients Who Die in Hospital in Canada
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 24
Issue 4
10.3747/co.24.3797
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Meeting Report

ASCO 2017 Meeting Summary: Updates to Practice-Changing Studies in Untreated Non-Hodgkin Lymphoma

by
P. Laneuville
1,
J.F. Larouche
2,
A. Tosikyan
3 and
A. Christofides
4,*
1
McGill University and McGill University Health Center, Montreal, QC, Canada
2
Laval University and Centre Hospitalier Affilié Universitaire de Québec, Laval, QC, Canada
3
Université de Montreal and Hôpital du Sacré-Coeur de Montréal, Montreal, QC, Canada
4
IMPACT Medicom Inc., Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2017, 24(4), 262-370; https://doi.org/10.3747/co.24.3797
Submission received: 9 May 2017 / Revised: 5 June 2017 / Accepted: 7 July 2017 / Published: 1 August 2017

Abstract

The 2017 annual meeting of the American Society of Clinical Oncology took place in Chicago, Illinois, 2–6 June. At the meeting, results from key studies in the first-line treatment of indolent non-Hodgkin lymphoma (iNHL) were presented. Of those studies, two were selected for oral presentations: 9-year follow-up data from the STiL NHL1 trial, which compared the efficacy and safety of bendamustine plus rituximab (BR) with those of rituximab plus cyclophosphamide–vincristine–prednisone–doxorubicin (R-CHOP); and 5-year follow-up data from the bright study, which compared BR with R-CHOP and R-CVP (rituximab plus cyclophosphamide–vincristine–prednisone) combined. Our meeting report describes the foregoing studies and includes interviews with key investigators, plus commentaries from three Quebec hematologists on the potential effects for Canadian practice.
Keywords: indolent non-Hodgkin lymphoma; untreated; front-line treatment; first-line treatment indolent non-Hodgkin lymphoma; untreated; front-line treatment; first-line treatment

Share and Cite

MDPI and ACS Style

Laneuville, P.; Larouche, J.F.; Tosikyan, A.; Christofides, A. ASCO 2017 Meeting Summary: Updates to Practice-Changing Studies in Untreated Non-Hodgkin Lymphoma. Curr. Oncol. 2017, 24, 262-370. https://doi.org/10.3747/co.24.3797

AMA Style

Laneuville P, Larouche JF, Tosikyan A, Christofides A. ASCO 2017 Meeting Summary: Updates to Practice-Changing Studies in Untreated Non-Hodgkin Lymphoma. Current Oncology. 2017; 24(4):262-370. https://doi.org/10.3747/co.24.3797

Chicago/Turabian Style

Laneuville, P., J.F. Larouche, A. Tosikyan, and A. Christofides. 2017. "ASCO 2017 Meeting Summary: Updates to Practice-Changing Studies in Untreated Non-Hodgkin Lymphoma" Current Oncology 24, no. 4: 262-370. https://doi.org/10.3747/co.24.3797

APA Style

Laneuville, P., Larouche, J. F., Tosikyan, A., & Christofides, A. (2017). ASCO 2017 Meeting Summary: Updates to Practice-Changing Studies in Untreated Non-Hodgkin Lymphoma. Current Oncology, 24(4), 262-370. https://doi.org/10.3747/co.24.3797

Article Metrics

Back to TopTop